FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 304:998-1003 April 23, 1981 Number 17 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Thromboxane A2 (TxA2), an arachidonic acid metabolite causing vasoconstriction and platelet aggregation, is a putative mediator of coronary-artery vasospasm. To determine whether platelet-released TxA2 causes coronary arterial vasospasm, we measured plasma thromboxane B2 (TxB2, the inactive hydration product of TxA2) in the radial-artery and coronary-sinus blood of seven patients and performed therapeutic trials of antiplatelet agents in nine. Although coronary-sinus TxB2 levels rose from the base line approximately fivefold with spontaneous ischemia, samples drawn early in ischemia showed no rise over base-line values. Although a 150 mg dose of aspirin reduced urinary dinor-TxB2 levels by over 75 per cent, it had no effect on the course of the chronic recurrent form of angina pectoris due to vasospasm ("vasotonic angina"). Similarly, indomethacin had no effect on the frequency or duration of ischemia. TxA2 is unlikely to cause vasotonic angina, but it may be released during coronary vasospasm.

This article has been cited by other articles:

• Yoshimura, M., Oshima, T., Hiraga, H., Nakano, Y., Matsuura, H., Yamagata, T., Shiode, N., Kato, M., Kambe, M., Kajiyama, G. (1998). Increased cytosolic free Mg2+ and Ca2+ in platelets of patients with vasospastic angina. Am. J. Physiol. Regul. Integr. Comp. Physiol. 274: R548-R554 [Abstract] [Full Text]  
• Figueras, J., Lidon, R. M. (1995). Early Morning Reduction in Ischemic Threshold in Patients With Unstable Angina and Significant Coronary Disease. Circulation 92: 1737-1742 [Abstract] [Full Text]  
• Nichols, W. W., Mehta, J., Wargovich, T. J., Franzini, D., Lawson, D. (1989). Reduced Myocardial Neutrophil Accumulation and Infarct Size Following Thromboxane Synthetase Inhibitor or Receptor Antagonist. ANGIOLOGY 40: 209-221 [Abstract]  
• Levy, R., Moskowitz, J (1982). Cardiovascular research: decades of progress, a decade of promise. Science 217: 121-129 [Abstract]